Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Adimmune Corporation

Market Cap 7.46B 237M 204M 188M 176M 331M 22.42B 335M 2.22B 867M 10.95B 888M 869M 37.94B P/E Ratio 2024
-34.7x
P/E Ratio 2025 -33.2x
Enterprise Value 8.07B 256M 221M 203M 191M 358M 24.25B 363M 2.4B 938M 11.85B 961M 941M 41.06B EV / Sales 2024
5.53x
EV / Sales 2025 6.14x
Free-Float
70.23%
Yield 2024 *
-
Yield 2025 -
1 day+0.28%
1 week-0.84%
Current month+3.21%
3 months+1.14%
6 months-8.05%
Current year-6.60%
1 week 17.45
Extreme 17.45
18.45
1 month 16.8
Extreme 16.8
18.45
Current year 16.8
Extreme 16.8
21.5
1 year 15.9
Extreme 15.9
22.5
3 years 15.9
Extreme 15.9
38.2
5 years 15.9
Extreme 15.9
56.2
10 years 15.9
Extreme 15.9
79.8
Manager TitleAgeSince
Chief Executive Officer - 2019-06-19
Director of Finance/CFO - 2020-12-31
Chief Tech/Sci/R&D Officer - 2022-01-25
Director TitleAgeSince
Director/Board Member - 2019-06-19
Director/Board Member - 2011-08-14
Director/Board Member - 2017-06-28
Change 5-day change 1-year change 3-year change Capi.($)
+0.28%-0.84%+3.81%-52.48% 235M
+0.46%-3.22%+16.20%-20.25% 62.28B
-5.71%-0.69%+58.58%+208.79% 60.59B
+2.86%+33.20%+33.20%+33.20% 39.55B
-1.84%+7.78%-55.82%-63.26% 36.8B
-0.70%+1.69%+52.04%-33.78% 29.53B
-6.04%-0.39%+50.52%+65.98% 21.68B
+4.45%+9.89%+95.46%-58.64% 19.8B
+1.24%+1.04%-4.09%+126.32% 16.96B
-0.96%-2.60%+52.63%+93.85% 16.16B
Average -1.08%+2.66%+30.25%+29.97% 30.36B
Weighted average by Cap. -1.40%+2.77%+30.05%+43.78%

Financials

2024 2025
Net sales 1.56B 49.4M 42.58M 39.21M 36.79M 69.04M 4.68B 69.93M 464M 181M 2.28B 185M 181M 7.92B 1.4B 44.47M 38.33M 35.3M 33.11M 62.14M 4.21B 62.94M 418M 163M 2.06B 167M 163M 7.13B
Net income -243M -7.7M -6.64M -6.11M -5.74M -10.76M -729M -10.9M -72.31M -28.21M -356M -28.9M -28.28M -1.23B -240M -7.61M -6.56M -6.04M -5.67M -10.64M -721M -10.77M -71.46M -27.88M -352M -28.56M -27.95M -1.22B
Net Debt 140M 4.43M 3.82M 3.51M 3.3M 6.19M 419M 6.27M 41.57M 16.22M 205M 16.61M 16.26M 710M 612M 19.43M 16.74M 15.42M 14.47M 27.15M 1.84B 27.5M 182M 71.16M 898M 72.89M 71.34M 3.11B
Logo Adimmune Corporation
Adimmune Corp is a Taiwan-based company mainly engaged in the research, development, processing, manufacturing, and sales of serums, vaccines, diagnostic reagents, biological agents, bacterial cultures, and raw materials. The Company's main products are influenza vaccines and non-influenza vaccines. Tetanus vaccines are used to prevent tetanus. Influenza vaccines are used to prevent seasonal influenza viruses. Tuberculin skin tests are used to determine whether a patient is infected with Mycobacterium tuberculosis. The Company primarily sells its products domestically and internationally.
Employees
564
Date Price Change Volume
26-06-15 17.70 NT$ +0.28% 691,193
26-06-12 17.65 NT$ +0.28% 872,799
26-06-11 17.60 NT$ -1.12% 1,164,451
26-06-10 17.80 NT$ +1.14% 2,986,071
26-06-09 17.60 NT$ -0.28% 908,050
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4142 Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!